KIF5B-ALK, a novel fusion oncokinase identified by an immunohistochemistry-based diagnostic system for ALK-positive lung cancer. - Wikidata - awgldk - TriplyDB

KIF5B-ALK, a novel fusion oncokinase identified by an immunohistochemistry-based diagnostic system for ALK-positive lung cancer.

KIF5B-ALK, a novel fusion oncokinase identified by an immunohistochemistry-based diagnostic system for ALK-positive lung cancer.

http://www.wikidata.org/entity/Q33433329

about

ALK Signaling and Target Therapy in Anaplastic Large Cell Lymphoma Evaluation of EML4-ALK fusion proteins in non-small cell lung cancer using small molecule inhibitors Molecular biology of lung cancer Crizotinib: A comprehensive review Clinical use of crizotinib for the treatment of non-small cell lung cancer The biology and treatment of EML4-ALK non-small cell lung cancer The role of the ALK receptor in cancer biology ALK evaluation in the world of multiplex testing: Network Genomic Medicine (NGM): the Cologne model for implementing personalised oncology Tackling ALK in non-small cell lung cancer: the role of novel inhibitors New treatment options for ALK+ advanced non-small-cell lung cancer: critical appraisal of ceritinib Molecular mechanisms that underpin EML4-ALK driven cancers and their response to targeted drugs Personalized treatment options for ALK-positive metastatic non-small-cell lung cancer: potential role for Ceritinib The distinctive nature of adenocarcinoma of the lung Treating patients with ALK-positive non-small cell lung cancer: latest evidence and management strategy Molecular testing guideline for selection of lung cancer patients for EGFR and ALK tyrosine kinase inhibitors: guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Targeting EML4-ALK driven non-small cell lung cancer (NSCLC)Review of the current targeted therapies for non-small-cell lung cancer Role of molecular studies in the diagnosis of lung adenocarcinoma Molecular pathology of lung cancer: key to personalized medicine.Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer.The Hsp90 inhibitor IPI-504 rapidly lowers EML4-ALK levels and induces tumor regression in ALK-driven NSCLC models.Identification of anaplastic lymphoma kinase fusions in renal cancer: large-scale immunohistochemical screening by the intercalated antibody-enhanced polymer method.ROS1 and ALK fusions in colorectal cancer, with evidence of intratumoral heterogeneity for molecular drivers.Two novel ALK mutations mediate acquired resistance to the next-generation ALK inhibitor alectinib ALK and crizotinib: after the honeymoon…what else? Resistance mechanisms and new therapies to overcome it Inhibitors of the anaplastic lymphoma kinase Renal cell carcinoma with novel VCL-ALK fusion: new representative of ALK-associated tumor spectrum International association for the study of lung cancer/american thoracic society/european respiratory society international multidisciplinary classification of lung adenocarcinoma The Structural Characterization of Tumor Fusion Genes and Proteins ALK and NSCLC: Targeted therapy with ALK inhibitors In Vitro Drug Sensitivity Tests to Predict Molecular Target Drug Responses in Surgically Resected Lung Cancer Spectrum of oncogenic driver mutations in lung adenocarcinomas from East Asian never smokers A novel, highly sensitive antibody allows for the routine detection of ALK-rearranged lung adenocarcinomas by standard immunohistochemistry.Differential expression of CRKL and AXL genes in lung adenocarcinoma subtypes according to the epidermal growth factor receptor and anaplastic lymphoma kinase gene status.ALK-rearrangements and testing methods in non-small cell lung cancer: a review Chromosomal and genomic changes in lung cancer.Matrix metalloproteinase (MMP)-13 regulates mammary tumor-induced osteolysis by activating MMP9 and transforming growth factor-beta signaling at the tumor-bone interface.Clinical characteristics and outcomes of patients with primary lung adenocarcinoma harboring ALK rearrangements detected by FISH, IHC, and RT-PCR.An inflammatory myofibroblastic tumor exhibiting immunoreactivity to KIT: a case report focusing on a diagnostic pitfall.Identification and characterization of ALK kinase splicing isoforms in non-small-cell lung cancer.

P2860

Q21129306-07F1BA0C-95DD-4425-8862-BD393E682E5F Q24595585-F9DDAEC3-D46E-481F-A56D-BCBE90CEA9D7 Q24606677-115DD2FA-2079-4D5A-94A0-FD9B5CA2841A Q24624083-F96BA9E5-E105-4E0D-9D0C-576FC78DC59E Q24630466-A479DC87-2BF3-43BC-A7A2-02F4EC3652A4 Q24632625-3B7C25B9-30AF-4CA3-9AD4-787B48F6A31D Q26738384-16931E69-C2B6-427F-992B-4BDF6371E925 Q26738387-9E22DFFF-7683-499F-8747-C82740094149 Q26740329-99FB8B5F-DD33-4EE8-AED5-160CD15C3962 Q26746230-B9465944-4710-4A24-80E7-4585D20D87D7 Q26769659-B37F21B3-23F0-4058-8E99-7AD4E5543572 Q26775817-0B4A5BBE-678C-4660-BA2A-751DEEBD51E0 Q26781159-DC395024-9762-40EB-B55D-48ADD721A458 Q26795555-6D0D4850-5E1A-44BD-87F3-1EC6856E1E8B Q26828860-52615E8D-9042-4855-8A22-CDF7736BB6D2 Q27002155-86EC1AF1-7CAC-4E44-ACDE-C432BEFB6D44 Q27015079-62BF8E9F-786F-4B43-BB92-9C9CFAB9BD9A Q27023212-B60A352F-1275-4A80-BEF3-E29A875EF2AB Q27691299-C2E1692A-D17F-45DB-8721-F66499000750 Q27851588-802B4E25-546C-4C87-BDBD-631CA8FEAC91 Q27851619-CFFB4180-EA4C-4656-B048-4B21BF7F5DEF Q27851704-96822B00-64F0-448F-8B45-421D2C0F896C Q27852699-FC842545-CE77-42B7-8375-0F13C5630FC5 Q27853072-2A414D58-9821-4945-9A27-E47DD2846F78 Q28083386-7CCCFF8B-DBED-40FC-93EA-091FA68F765D Q28267124-FF6D00BB-8938-4282-8724-4DECF62AE27F Q28298351-D1A6A5E3-BAD7-45C3-BE50-92422287F45A Q28303718-95B301DF-0770-4E25-A9BA-5E5988CFB14B Q28386511-3966DE1F-4978-428F-BAB0-C48CBDC7B920 Q28393324-8FDDE680-54AD-41F3-89E2-3B694DEA08A2 Q28551308-872D8790-1E9D-46E9-8177-84651D8606F1 Q28742090-1FD18166-546B-45CD-98B5-393069F08200 Q33699169-15759622-9E0F-4DE5-9D35-8BD2B2613A65 Q33733522-6D1672A4-70DF-4D42-A5BA-88D1A704C12D Q33776835-6F0C8A14-6A33-4673-A72C-79EE62B49877 Q33781119-828E1682-912C-41F2-B8C2-1017DAA1716E Q33820604-48B42E5E-8A32-4130-8180-02CA4C0AC6D3 Q33844713-BF489F1D-A0BD-4938-9210-492C0A42B688 Q33850759-EDF4AFFA-77FF-4192-AD71-142B3CC463A0 Q33897022-22335CC8-47C6-4BC6-9805-3AB60C91D005

P2860

KIF5B-ALK, a novel fusion oncokinase identified by an immunohistochemistry-based diagnostic system for ALK-positive lung cancer.

http://www.wikidata.org/entity/Q33433329

description

2009 nî lūn-bûn

@nan

2009 թուականի Ապրիլին հրատարակուած գիտական յօդուած

@hyw

2009 թվականի ապրիլին հրատարակված գիտական հոդված

@hy

2009年の論文

@ja

2009年論文

@yue

2009年論文

@zh-hant

2009年論文

@zh-hk

2009年論文

@zh-mo

2009年論文

@zh-tw

2009年论文

@wuu

name

KIF5B-ALK, a novel fusion onco ...... for ALK-positive lung cancer.

@ast

KIF5B-ALK, a novel fusion onco ...... for ALK-positive lung cancer.

@en

type

label

KIF5B-ALK, a novel fusion onco ...... for ALK-positive lung cancer.

@ast

KIF5B-ALK, a novel fusion onco ...... for ALK-positive lung cancer.

@en

prefLabel

KIF5B-ALK, a novel fusion onco ...... for ALK-positive lung cancer.

@ast

KIF5B-ALK, a novel fusion onco ...... for ALK-positive lung cancer.

@en

P1433

Q33433329-E24803DB-CB6B-4484-9713-279181128A54

P1476

Q33433329-00F47753-8394-43E4-A189-6E2F2D149762

P2093

Q33433329-1A815FA5-B39B-4940-99C9-BE069981C228

Q33433329-3F87D8BC-E927-456E-8134-C32062C4187D

Q33433329-6B032BC5-214B-4891-926E-82CBD8263CA2

Q33433329-752872D4-AD9B-4A09-80A7-0D59A2C83A68

Q33433329-8A7A3871-1C54-430F-889F-F60B906B5E2E

Q33433329-93E3AF4C-20C5-4376-A64D-2177E480B3F5

Q33433329-A528C2BB-409F-4920-85D9-B3C0C8840B74

Q33433329-B19847FC-4C08-4F99-99D8-4631F9E7859F

Q33433329-B271EF40-AA7C-4A5A-9CCF-49984497E2E8

Q33433329-C5913ABF-5C6D-4E59-A709-7829DEC5C643

P304

Q33433329-7B3894D5-0E4B-419A-91A2-705FA1C766D8

P31

Q33433329-2F410995-C81A-4778-BB89-953D2978E054

P356

Q33433329-56D0F830-EEE5-4919-A7AF-475E899EA7F2

P407

Q33433329-37AF0458-1BE6-4CBE-AE0E-844F9D583D0C

P433

Q33433329-0F7AAE2D-EF53-48EA-BBD0-E8F867B2A3F6

P478

Q33433329-DA9F6546-B3DD-478F-915B-D8F32FBFA94D

P50

Q33433329-20F74E20-7973-4BA5-85CA-9F9077F93C81

Q33433329-FC41A818-B5AE-476D-A168-9C0D1727F50B

P577

Q33433329-C2540E32-0A93-4C38-A06D-C70B90AC6B2E

P698

Q33433329-E61E4F0E-69D1-46F8-9C17-00D0A62CE70E

P921

Q33433329-9B867382-51F0-46A8-97A6-8A6016BA6257

Q33433329-d999ffaa-d71b-49da-94b7-54532411bb3c

P356

1078-0432.CCR-08-3248

P1433

Clinical Cancer Research

P1476

KIF5B-ALK, a novel fusion onco ...... for ALK-positive lung cancer.

@en

P2093

Hiroyuki Mano

http://www.w3.org/2001/XMLSchema#string

Ken Nakagawa

http://www.w3.org/2001/XMLSchema#string

Manabu Soda

http://www.w3.org/2001/XMLSchema#string

Sakae Okumura

http://www.w3.org/2001/XMLSchema#string

Satoko Hatano

http://www.w3.org/2001/XMLSchema#string

Shuji Takada

http://www.w3.org/2001/XMLSchema#string

Toshihide Ueno

http://www.w3.org/2001/XMLSchema#string

Yoshihiro Yamashita

http://www.w3.org/2001/XMLSchema#string

Young Lim Choi

http://www.w3.org/2001/XMLSchema#string

Yuichi Ishikawa

http://www.w3.org/2001/XMLSchema#string

P304

3143-3149

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1158/1078-0432.CCR-08-3248

http://www.w3.org/2001/XMLSchema#string

P407

P433

9

http://www.w3.org/2001/XMLSchema#string

P478

15

http://www.w3.org/2001/XMLSchema#string

P50

Kentaro Inamura

P577

2009-04-21T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

19383809

http://www.w3.org/2001/XMLSchema#string

P921

immunohistochemistry